ISRCTN54829649 https://doi.org/10.1186/ISRCTN54829649

Chemotherapy Followed by Surgery versus Surgery Alone in Patients with Oesophageal Squamous Cell Carcinoma

Submission date 23/08/2010	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 25/10/2010	**Overall study status** Completed	
Last Edited 05/08/2021	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Jurjen Boonstra

Contact details
Dr Molewaterplein 50
Rotterdam
Netherlands
3000 CA

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Chemotherapy Followed by Surgery versus Surgery Alone in Patients with Oesophageal Squamous Cell Carcinoma: Long-term Results of a Randomised Controlled Trial

Study objectives

Patients with oesophageal sqaumous cell carcinoma who receive preoperative chemotherapy have equal or better overall survival compared to patients who undergo surgery alone

Ethics approval required
Old ethics approval format

Ethics approval(s)
The study protocol was approved by the Ethics Committee of all participating institutions, and by the Review Board of the Netherlands Cancer Foundation

Study design
Multicentre randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Oesophageal squamous cell carcinoma

Interventions
Random assignment was stratified by age, gender, weight loss in the past four months and length of the tumor as measured by esophago-gastroscopy.
Patients assigned to preoperative chemotherapy (CS group) received neoadjuvant etoposide plus cisplatin. Cisplatin, at a dose of 80 mg/m2, was given intravenously over 4 hours on day one of each cycle preceded and followed by adequate hydration. Etoposide, at a dose of 100 mg/m2, was administered intravenously over 2 hours on day 1 (before cisplatin) and day 2, followed by etoposide 200 mg/m2 orally on days 3 and 5. This course was repeated in week 4. In case of clinical response, two subsequent courses of chemotherapy were administered in week 8 and 11. Surgery was performed between 4 and 6 weeks after the last course of chemotherapy.

Patients assigned to surgery alone (S group) recieved surgery as soon as possible.

Surgery protocol for both treatment groups:
For carcinomas of the upper half of the intra-thoracic esophagus a right-sided thoracotomy was performed. For carcinomas of the lower half of the intra-thoracic esophagus a transhiatal esophagectomy was preferred. The tumor and its adjacent lymph nodes were dissected en bloc. The left gastric artery was transected at its origin, with resection of local lymph nodes. The continuity of the digestive tract was restored by means of gastric tube reconstruction or colonic interposition with a cervical anastomosis.

Intervention Type
Other

Phase
Not Applicable

Primary outcome(s)
Overall survival

Key secondary outcome(s))
Disease free survival

Completion date
01/01/1996

Eligibility

Key inclusion criteria
1. Histologically confirmed squamous cell carcinoma of the intra-thoracic oesophagus
2. No evidence of distant metastases
3. Absence of unresectable local disease
4. Below 80 years of age
5. In adequate physical condition (Karnofsky score >70) to undergo surgery
6. Adequate hepatic, renal and bone marrow function

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
169

Key exclusion criteria
1. Synchronous cancer
2. Tumour localization in the cervical oesophagus (upper border, <18 cm from the incisor teeth)
3. Severe cardiovascular or pulmonary disease
Patients with previous malignancies were eligible if more than 5 years had elapsed from diagnosis without evidence of tumor recurrence; exceptions were made for adequately treated basal cell cancer of the skin or carcinoma in situ of the cervix.

Date of first enrolment
01/01/1989

Date of final enrolment
01/01/1996

Locations

Countries of recruitment
Netherlands

Study participating centre
Dr Molewaterplein 50
Rotterdam
Netherlands
3000 CA

Sponsor information

Organisation
Erasmus Medical Centre (Netherlands)

ROR
https://ror.org/018906e22

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Erasmus Medical Centre (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		19/05/2011	05/08/2021	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes